Q3 Earnings Forecast for Omnicell Issued By Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research lowered their Q3 2025 earnings per share estimates for shares of Omnicell in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.23 for the quarter, down from their prior forecast of $0.31. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2025 earnings at $0.38 EPS, FY2025 earnings at $0.81 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.36 EPS and FY2026 earnings at $1.08 EPS.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Benchmark reaffirmed a “buy” rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $52.33.

Omnicell Trading Down 0.9 %

NASDAQ OMCL opened at $37.39 on Monday. The firm’s fifty day moving average is $42.14 and its two-hundred day moving average is $43.76. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market cap of $1.73 billion, a PE ratio of 138.49, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Omnicell in the 4th quarter worth about $37,000. Van ECK Associates Corp grew its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new position in Omnicell during the 4th quarter valued at about $53,000. Finally, First Horizon Advisors Inc. raised its position in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is currently owned by company insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.